Travere Therapeutics, Inc. (TVTX)

Several events have impacted Travere Therapeutics' stock price over the past six months. The full FDA approval for FILSPARI in FSGS led to a stock increase. The Q1 2026 earnings report showed a loss per share but an adjusted net income that beat analyst estimates. The Q4 2025 earnings report met analyst expectations. An FDA request for additional data caused a pre-market stock drop. The Q3 2025 earnings report resulted in a stock surge. Overall, the share price increased significantly between May 5, 2025, and May 1, 2026.

There is no explicit indication of significant demand seasonality for Travere Therapeutics' products and services. The company focuses on rare diseases, which typically represent ongoing, unmet medical needs rather than conditions with seasonal fluctuations. The consistent reporting of strong sales growth and new patient start forms suggests steady demand driven by medical necessity.

Travere Therapeutics is a biopharmaceutical company focused on identifying, developing, and delivering therapies for rare kidney and metabolic diseases. Its major commercial products include FILSPARI for IgA Nephropathy and FSGS, Thiola and Thiola EC for cystinuria, Chenodal for radiolucent gallstones, and Cholbam for bile acid synthesis and peroxisomal disorders. The company's pipeline includes Pegtibatinase (TVT-058) in Phase 3 development for classical homocystinuria (HCU).

Travere Therapeutics is headquartered in San Diego, California. FILSPARI has been launched in Germany, Austria, Switzerland, Luxembourg, and the UK through a collaboration with CSL Vifor. A New Drug Application for sparsentan is expected to be submitted in Japan in 2026 by Chugai Pharmaceutical.

Travere Therapeutics has maintained a positive brand reputation due to its commitment to rare diseases and clinical advancements. The full FDA approval of FILSPARI for FSGS enhanced its reputation. The company emphasizes a patient-inspired approach, offering personalized support services. An earlier FDA data request caused temporary concerns, but the subsequent full approval for FSGS has likely mitigated any lasting negative impact. Consistent reporting of strong physician and patient confidence in its products.

Travere Therapeutics' ownership is primarily held by institutional investors, who hold approximately 55.93% to 57.57% of the company's stock. Public and individual investors hold approximately 40.86% to 42.56% of the shares. Insider ownership is relatively smaller, around 1.51% to 4.44%, with Ruth Shepley noted as a significant individual shareholder.